Galapagos Ontvangt Transparantiemeldingen van Bank of America

Brusselse beurs - Galapagos verdwijnt uit de Bel20-index, Montea wordt erin opgenomen

Biotechbedrijf Galapagos verdwijnt maandag uit de Bel20, de sterindex met de twintig belangrijkste aandelen van de Brusselse beurs. In de plaats komt vastgoedvennootschap Montea. Dat maakte ...

Galapagos Stock Surges On Strategic Spin-Off And Restructuring Plans: Retail Turns Extremely Bullish

Belgium-based biotech company Galapagos NV's (GLPG) U.S.-listed shares rose over 4% in Wednesday's premarket after it announced a significant restructuring plan, including a spin-off into two publicly traded entities and …

Galapagos Announces Board Decision To Initiate Wind-Down Of Cell Therapy Activities

Galapagos to Wind Down Cell Therapy Activities, Impacting 365 Employees

Galapagos stock holds steady as Raymond James maintains Market Perform rating

Investing.com - Raymond James has reiterated its Market Perform rating on Galapagos NV (NASDAQ:GLPG) following the company's announcement of mixed results from two Phase 2 studies of its TYK2 inhibitor …

Repeat & Correct: Galapagos to Look at Strategic Alternatives Following Mixed Results From Two Studies

Galapagos to Look At Strategic Alternatives After Drug Doesn't Meet Trial Goal

Galapagos Presented New Atalanta-1 Cell Therapy Data In MCL

Galapagos NV (GLPG.VI)

Check a company's competitiveness in the job market with alternative data that tracks hiring, job openings, and more.

GLPG: Transforming with €3B cash, exiting cell therapy, and targeting de-risked immunology/oncology deals

Galapagos Is Maintained at Sector Perform by RBC Capital

Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript

Good day, and thank you for standing by. Welcome to the Galapagos Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. …

GLPG: Cell therapy business to be wound down; focus shifts to BD and leveraging EUR 3B+ cash position

GLPG: Cell therapy business wind down drives €204.8M impairment and €461.3M net loss; cash at €3.05B

GLPG: Transformation underway with cell therapy exit, major impairment, and strong cash outlook

Galapagos NV (GLPGA.XC)

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios and more.

Brusselse beurs - Galapagos verdwijnt uit de Bel20-index, Montea wordt erin opgenomen

Biotechbedrijf Galapagos verdwijnt maandag uit de Bel20, de sterindex met de twintig belangrijkste aandelen van de Brusselse beurs. In de plaats komt vastgoedvennootschap Montea. Dat maakte beursuitbater Euronext eerder bekend. …

Beursblik: focus op opsplitsingplan bij jaarcijfers Galapagos

(ABM FN-Dow Jones) Bij de jaarcijfers die Galapagos woensdag nabeurs publiceert, zullen beleggers letten op eventuele nieuwe informatie over de recent aangekondigde opsplitsing in twee beursgenoteerde ...